Study Title
Takeda 205
Purpose
To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole 30 or 60 mg for 8 to 12 weeks in pediatric subjects aged 1 to 11 years, inclusive, with Erosive Esophagitis.
Eligibility
Pediatric subjects aged 1 to 11 years, inclusive, with Erosive Esophagitis
Study Process
Subjects 1-11 years old with Erosive Esophagitis will be enrolled in the study. Subjects will undergo an Endoscopy and will have lab tests at most visits
Trial Details
Investigator:
Sunny Hussain, M.D.
IRB:
Willis-Knighton
IRB Number:
Trial Type:
Drug
Sponsor:
Takeda
Contact Information:
(318) 212-8130
http://www.wkpgis.com